Clinical trials: Gastro-Intestinal Disorders
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms
A Study of SGN-MesoC2 in Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms
- Trial name
- NCT06466187
- Testing
- PF-08052666
- Where
- 19 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Eosinophilic Esophagitis
Expanded Access Protocol for Patients With Eosinophilic Esophagitis
This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.
- Trial name
- NCT05095116
- Testing
- APT-1011 3 mg HS
- Where
- 35 sites in United States
- Sponsor
- Ellodi Pharmaceuticals, LP
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Gastric Cancer (GC), Colorectal Cancer
Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and…
- Trial name
- NCT07166263
- Testing
- NK510
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumors
A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no…
- Trial name
- NCT02442414
- Testing
- KBP-5209
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Breast Cancer, Prostate Cancer
Tempus Priority Study: A Pan-tumor Observational Study
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with…
- Conditions
- Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
- Trial name
- NCT05179824
- Testing
- Observation
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Tempus AI
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Advanced Cancer, Colorectal Cancer
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.
- Conditions
- Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
- Trial name
- NCT02745769
- Testing
- Ramucirumab, Merestinib, Abemaciclib
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312.
- Trial name
- NCT02144051
- Testing
- AZD5312
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Gastric Cancer, Non-small Cell Lung Cancer
Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers
Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist.
- Conditions
- Gastric Cancer, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05800418
- Testing
- Ramucirumab Injection, Ramucirumab Injection [Cyramza]
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Heartburn
A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes
This decentralized, randomized, double-blind, placebo-controlled, two-period crossover study will evaluate whether PepZinGI® (zinc-L-carnosine) reduces food-triggered heartburn compared with placebo.
- Trial name
- NCT07379645
- Testing
- PepZinGI
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NutriScience Innovations, LLC
Diabetes Mellitus, Type 2
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
This is a Phase 4, prospective, open label, randomized, parallel controlled multicenter trial in which metformin extended release (XR) will be compared with metformin immediate release (IR) for the gastrointestinal tolerability…
- Trial name
- CONSENT (NCT02252965)
- Testing
- Metformin IR, Metformin XR
- Where
- Germany
- Volunteers
- 532 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
GERD (Gastroesophageal Reflux Disease)
An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients
This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.
- Trial name
- NCT07678177
- Where
- South Korea
- Volunteers
- 5,384 people
- Sponsor
- HK inno.N Corporation
Gastroesophageal Reflux Disease (GERD)
Retrospective Observational Study on GERD Management in General Hospitals in Korea
A RetrospectiVe ObservatIoNal Study of a CurrEnt Status and its Management of GERD (GastroEsophageal Reflux Disease) in General HOspitals in Korea
- Trial name
- VINCERO (NCT06974903)
- Where
- South Korea
- Volunteers
- 13,750 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Small Bowel Obstruction, Gastrointestinal Hemorrhage
Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity
This study will evaluate the use of RightBio Metrics' RightSpot device used to determine if there is proper placement of a nasogastric or orogastric tube.
- Trial name
- NCT01561729
- Testing
- RightSpot pH Indicator, Chest radiograph
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- RightBio Metrics
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Gastroesophageal Reflux Disease
Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.
To describe the change of impact of reflux symptoms on the everyday life perceived by patients before and after 4 weeks treatment by using GERD Impact Scale questionnaire (GIS) by total GERD patient population and by treatment…
- Trial name
- NCT00786773
- Where
- 18 sites in Vietnam
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Magnetic Esophageal Sphincter implant is intended to reinforce Esophageal Sphincter function in the treatment of Gastroesophageal Reflux Disease (GERD)
- Trial name
- NCT01058070
- Testing
- Torax Medical, Inc. LINX Reflux Management System
- Where
- 5 sites in United States, Italy and 1 more
- Volunteers
- 44 people
- Sponsor
- Torax Medical Incorporated
Gastro Esophageal Reflux
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
- Trial name
- NCT06025773
- Testing
- Lansoprazole 15 mg, Lansoprazole 15mg/Calcium carbonate 600mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
High-grade Dysplasia in Barrett Esophagus, Non Small Cell Lung Cancer
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Photodynamic therapy (PDT) uses a combination of a drug, porfimer sodium, and a light from a non heated laser. The activation of the drug is done by illuminating abnormal areas using a fiber optic device.
- Conditions
- High-grade Dysplasia in Barrett Esophagus, Non Small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT01256203
- Testing
- Solar Protection Formula SPF® 60, Photobiological testing
- Sponsor
- Pinnacle Biologics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.